Literature DB >> 32569750

Reply.

Ferdinando D'Amico1, Silvio Danese2, Laurent Peyrin-Biroulet3.   

Abstract

Entities:  

Year:  2020        PMID: 32569750      PMCID: PMC7305756          DOI: 10.1016/j.cgh.2020.06.038

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


× No keyword cloud information.
We appreciate the thoughtful comments of Perisetti and colleagues. In line with our article they support our hypothesis that diarrhea in patients with coronavirus disease 2019 (COVID-19) may be related not only to the activity of the new coronavirus but also to the drugs used for its treatment as antibiotics and antivirals. Interestingly, they add that even the cytokine storm generated by COVID-19 may play a role in diarrhea etiopathogenesis by influencing the gut-brain axis and causing increased intestinal permeability. If this theory is confirmed, the use of biological drugs such as tumor necrosis factor inhibitors, which selectively block a proinflammatory cytokine and small molecules such as JAK inhibitors, that target entire inflammatory pathways could represent a possible therapeutic option. Two case reports have previously described cases of COVID-19 patients with inflammatory bowel diseases successfully treated with anti–tumor necrosis factor drug or JAK inhibitor, but the impact of these therapies on diarrhea has not yet been investigated.
  3 in total

1.  COVID-19 cytokine storm: the interplay between inflammation and coagulation.

Authors:  Ricardo J Jose; Ari Manuel
Journal:  Lancet Respir Med       Date:  2020-04-27       Impact factor: 30.700

2.  Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib.

Authors:  Jeffrey Jacobs; Kindra Clark-Snustad; Scott Lee
Journal:  Inflamm Bowel Dis       Date:  2020-06-18       Impact factor: 5.325

3.  Pediatric Crohn Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated With Infliximab.

Authors:  Michael T Dolinger; Hannibal Person; Rachel Smith; Lauren Jarchin; Nanci Pittman; Marla C Dubinsky; Joanne Lai
Journal:  J Pediatr Gastroenterol Nutr       Date:  2020-08       Impact factor: 3.288

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.